曲妥珠单抗联合新辅助化疗在乳腺癌患者中的应用效果

Application effects of Trastuzumab combined with neoadjuvant chemotherapy in patients with breast cancer

目的:探讨曲妥珠单抗联合新辅助化疗在乳腺癌患者中的应用效果。方法:选取2022年1月至2023年6月该院收治的100例乳腺癌患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各50例。对照组采用新辅助化疗方案(多西他赛+卡铂)治疗,观察组在对照组基础上联合曲妥珠单抗治疗,比较两组客观缓解率(ORR),治疗前后血清肿瘤标志物[糖类抗原15-3(CA15-3)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)]水平、生命质量[乳腺癌患者生命质量测定量表(FACT-B)]评分,以及不良反应发生率。结果:观察组ORR为70.00%(35/50),高于对照组的46.00%(23/50),差异有统计学意义(P<0.05);治疗后,观察组CA15-3、CYFRA21-1、CEA、VEGF水平均低于对照组,差异有统计学意义(P<0.05);治疗后,两组FACT-B评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组恶心、呕吐、血小板减少、口腔溃疡、肝功能异常、心脏毒性、手足综合征等并发症发生率比较,差异均无统计学意义(P>0.05)。结论:曲妥珠单抗联合新辅助化疗可提高乳腺癌患者ORR和生命质量评分,降低血清肿瘤标志物水平,效果优于单纯新辅助化疗。

Objective:To explore application effects of Trastuzumab combined with neoadjuvant chemotherapy in patients with breast cancer.Methods:A prospective study was conducted on 100 patients with breast cancer admitted to the hospital from January 2022 to June 2023.According to the random number table method,they were divided into control group and observation group,50 cases in each group.The control group was treated with neoadjuvant chemotherapy(Docetaxel+Carboplatin),while the observation group was treated with Trastuzumab on the basis of those of the control group.The objective response rate(ORR),the serum tumor markers[carbohydrate antigen 15-3(CA15-3),cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]levels before and after the treatment,the quality of life[functional assessment of cancer therapy-breast(FACT-B)]scores,and the incidence of adverse reactions were compared between the two groups.Results:The ORR of the observation group was 70.00%(35/50),which was higher than 46.00%(23/50)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CA15-3,CYFRA21-1,CEA and VEGF in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the FACT-B scores of the two groups were higher than those before the treatment,that in the observation group was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of complications such as nausea,vomiting,thrombocytopenia,oral ulcer,abnormal liver function,cardiotoxicity and hand-foot syndrome between the two groups(P>0.05).Conclusions:Trastuzumab combined with neoadjuvant chemotherapy can improve the ORR and the quality of life scores,and reduce the serum tumor marker levels in the patients with breast cancer.Moreover,it is superior to simple neoadjuvant chemotherapy.